With the advent of positron emission tomography (PET) imaging and CSF biomarkers (Aβ and tau), there have been significant advances in the diagnosis of AD and these procedures can identify early neuropathologic changes before the clinical and cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.